Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
Subscribe To Our Newsletter & Stay Updated